GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Insider Ownership

TSVT (2seventy bio) Insider Ownership : 6.38 % (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 2seventy bio's insider ownership is 6.38%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 2seventy bio's Institutional Ownership is 94.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 2seventy bio's Float Percentage Of Total Shares Outstanding is 82.64%.


2seventy bio Insider Ownership Historical Data

The historical data trend for 2seventy bio's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Insider Ownership Chart

2seventy bio Historical Data

The historical data trend for 2seventy bio can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Insider Ownership 4.12 4.10 4.50 4.50 4.60 6.43 6.40 6.40 6.40 6.38

2seventy bio Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


2seventy bio Business Description

Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
William R. Sellers director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142